Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Cited by (1,000)

Items 101–200 of 1,000

1. Mutant p53 in Cancer Progression and Targeted Therapies
   Gaoyang Zhu, Chaoyun Pan, Jin‐Xin Bei, Bo Li, Liang Chen, Yang Xu, Xuemei Fu · 2020 · Frontiers in Oncology
2. New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy
   Jaclyn S. Long, Kevin M. Ryan · 2012 · Oncogene
3. Tumour suppression by p53: the importance of apoptosis and cellular senescence
   Valentina Zuckerman, Kamil Wolyniec, Ronit Vogt Sionov, Sue Haupt, Ygal Haupt · 2009 · The Journal of Pathology
4. CDC20, a potential cancer therapeutic target, is negatively regulated by p53
   T Kidokoro, Chizu Tanikawa, Yoichi Furukawa, Toyomasa Katagiri, Yusuke Nakamura, Koichi Matsuda · 2007 · Oncogene
5. DNA damage tolerance: a double-edged sword guarding the genome.
   Gargi Ghosal, Junjie Chen · 2013 · PubMed
6. New therapeutic strategies to treat human cancers expressing mutant p53 proteins
   Giovanni Blandino, Silvia Di Agostino · 2018 · Journal of Experimental & Clinical Cancer Research
7. Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide
   Eric L. Snyder, Bryan R. Meade, Cheryl C. Saenz, Steven F. Dowdy · 2004 · PLoS Biology
8. Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
   Pepita Gimenez‐Bonafé, Avelina Tortosa, Ricardo Pérez‐Tomás · 2009 · Current Cancer Drug Targets
9. Translating p53-based therapies for cancer into the clinic
   Sylvain Peuget, Xiaolei Zhou, Galina Selivanova · 2024 · Nature reviews. Cancer
10. Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
    Alexander H. Stegh · 2012 · Expert Opinion on Therapeutic Targets
11. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway
    Julia E. Kravchenko, Galina V. Ilyinskaya, Pavel G. Komarov, Larissa S. Agapova, Д. В. Кочетков, Evguenia Strom, Elena I. Frolova, I. E. Kovriga, Andrei V. Gudkov, Elena Feinstein et al. · 2008 · Proceedings of the National Academy of Sciences
12. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3
    Patton, John T., Mayo, Lindsey D., Singhi, Aatur D., Gudkov, Andrei V., Stark, George R., Jackson, Mark W. · 2006 · Cancer Research
13. Recent Advances in p53 Research and Cancer Treatment
    Kazufumi Suzuki, Hisahiro Matsubara · 2011 · BioMed Research International
14. Selective Killing of Cancer Cells by Leaf Extract of Ashwagandha: Identification of a Tumor-Inhibitory Factor and the First Molecular Insights to Its Effect
    Nashi Widodo, Kamaljit Kaur, Bhupal Govinda Shrestha, Yasuomi Takagi, Tetsuro Ishii, Renu Wadhwa, Sunil C. Kaul · 2007 · Clinical Cancer Research
15. Targeting Programmed Cell Death Using Small‐Molecule Compounds to Improve Potential Cancer Therapy
    Bowen Ke, Mao Tian, Jingjing Li, Bo Liu, Gu He · 2016 · Medicinal Research Reviews
16. Reactivation of mutant p53: molecular mechanisms and therapeutic potential
    Selivanova, G, Wiman, K G · 2007 · Oncogene
17. Targeting protein–protein interactions: Lessons from p53/MDM2
    Justin K. Murray, Samuel H. Gellman · 2007 · Biopolymers
18. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
    Mohell, N, Alfredsson, J, Fransson, Å, Uustalu, M, Byström, S, Gullbo, J, Hallberg, A, Bykov, V J N, Björklund, U, Wiman, K G · 2015 · Cell Death & Disease
19. APR-246 induces early cell death by ferroptosis in acute myeloid leukemia
    Birsen, Rudy, Larrue, Clement, Decroocq, Justine, Johnson, Natacha, Guiraud, Nathan, Gotanegre, Mathilde, Cantero-Aguilar, Lilia, Grignano, Eric, Huynh, Tony, Fontenay, Michaela et al. · 2021 · Haematologica
20. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis
    Fedor Nikulenkov, Clemens Spinnler, H. Li, Claudia Tonelli, Y Shi, Mikko M. Turunen, Teemu Kivioja, I Ignatiev, Alexander E Kel, Jussi Taipale et al. · 2012 · Cell Death and Differentiation
21. Mutant p53 reactivation by small molecules makes its way to the clinic
    Vladimir J.N. Bykov, Klas G. Wiman · 2014 · FEBS Letters
22. Regulating the p53 system through ubiquitination
    Yili Yang, Chou-Chi H. Li, Allan M. Weissman · 2004 · Oncogene
23. Crystal Structure of a Superstable Mutant of Human p53 Core Domain
    Andreas C. Joerger, Mark D. Allen, Alan Roy Fersht · 2004 · Journal of Biological Chemistry
24. Thioredoxin Reductase Inhibition for Cancer Therapy
    Radosveta Gencheva, Elias S.J. Arnér · 2021 · The Annual Review of Pharmacology and Toxicology
25. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database
    Vladimir J.N. Bykov · 2002 · Carcinogenesis
26. Zinc metalloproteins as medicinal targets
    Atilio I. Anzellotti, Nicholas P. Farrell · 2008 · Chemical Society Reviews
27. E3 ubiquitin ligases in cancer and implications for therapies
    Dong Wang, Leina Ma, Bin Wang, Jia Liu, Wenyi Wei · 2017 · Cancer and Metastasis Reviews
28. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance
    Tessoulin, Benoît, Descamps, Géraldine, Moreau, Philippe, Maïga, Sophie, Lodé, Laurence, Godon, Catherine, Marionneau-Lambot, Séverine, Oullier, Thibauld, Le Gouill, Steven, Amiot, Martine et al. · 2014 · Blood
29. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
    Peng, X, Zhang, M-Q-Z, Conserva, F, Hosny, G, Selivanova, G, Bykov, V J N, Arnér, E S J, Wiman, K G · 2013 · Cell Death & Disease
30. Limiting the power of p53 through the ubiquitin proteasome pathway
    Vinod Pant, Guillermina Lozano · 2014 · Genes & Development
31. Exploiting ferroptosis vulnerabilities in cancer
    Toshitaka Nakamura, Marcus Conrad · 2024 · Nature Cell Biology
32. Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme
    England, Bryant, Huang, Tiangui, Karsy, Michael · 2013 · Tumor Biology
33. Small Molecule Structure Correctors Abolish Detrimental Effects of Apolipoprotein E4 in Cultured Neurons
    Chen, Hung-Kai, Liu, Zhaoping, Meyer-Franke, Anke, Brodbeck, Jens, Miranda, Rene D., McGuire, James G., Pleiss, Michael A., Ji, Zhong-Sheng, Balestra, Maureen E., Walker, David W. et al. · 2012 · Journal of Biological Chemistry
34. Targeting the DNA Damage Response in Cancer
    Mats E. Ljungman · 2009 · Chemical Reviews
35. Recent advances in p53 research: an interdisciplinary perspective
    Magali Olivier, Audrey Petitjean, Virginie Marcel, Aurélia Pétré, Mounia Mounawar, Amelie Plymoth, Claude Caron de Fromentel, Pierre L. Hainaut · 2008 · Cancer Gene Therapy
36. Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway
    Xie, Haibiao, Ma, Kaifang, Zhang, Kenan, Zhou, Jingcheng, Li, Lei, Yang, Wuping, Gong, Yanqing, Cai, Lin, Gong, Kan · 2021 · Cell Death & Disease
37. HAMLET kills tumor cells by an apoptosis-like mechanism—cellular, molecular, and therapeutic aspects
    Catharina Svanborg, Helena Ågerstam, Annika Aronsson, Rolf Bjerkvig, Caroline Düringer, Walter Fischer, Lotta Gustafsson, Oskar Hällgren, Irene Leijonhuvud, Sara Snogerup Linse et al. · 2003 · Advances in cancer research
38. Current strategies to target p53 in cancer
    Fang Chen, Wenge Wang, Wafik S. El‐Deiry · 2010 · Biochemical Pharmacology
39. Differential effects of cell cycle regulatory protein p21WAF1/Cip1 on apoptosis and sensitivity to cancer chemotherapy
    Suxing Liu, Walter Robert Bishop, Ming Liu · 2003 · Drug Resistance Updates
40. Wild-Type p53: Tumors Can't Stand It
    Michael B. Kastan · 2007 · Cell
41. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death
    Wischhusen, J, Naumann, U, Ohgaki, H, Rastinejad, F, Weller, M · 2003 · Oncogene
42. Current developments of targeting the p53 signaling pathway for cancer treatment
    Jing Li Huang · 2020 · Pharmacology & Therapeutics
43. Update on NCI in vitro drug screen utilities
    Susan L. Holbeck · 2004 · European Journal of Cancer
44. Exploring the multiple roles of guardian of the genome: P53
    Wasim Feroz, Arwah Mohammad Ali Sheikh · 2020 · Egyptian Journal of Medical Human Genetics
45. Should mutant TP53 be targeted for cancer therapy?
    Zilu Wang, Andreas Strasser, Gemma L. Kelly · 2022 · Cell Death and Differentiation
46. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides
    Célia Floquet, Jules Deforges, Jean‐Pierre Rousset, Laure Bidou · 2010 · Nucleic Acids Research
47. Mutant p53 on the Path to Metastasis
    Qiaosi Tang, Zhenyi Su, Wei Gu, Anil K. Rustgi · 2019 · Trends in cancer
48. Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics
    Ainsley Mike Antao, Apoorvi Tyagi, Kye-Seong Kim, Suresh Ramakrishna · 2020 · Cancers
49. Myeloid malignancies: mutations, models and management
    Anne Murati, Mandy Brecqueville, Raynier Devillier, Julien Mozziconacci, Véronique Gelsi‐Boyer, Daniel Birnbaum · 2012 · BMC Cancer
50. The aflatoxin-induced TP53 mutation at codon 249 (R249S): Biomarker of exposure, early detection and target for therapy
    Doriane A. Gouas, Hong Shi, Pierre L. Hainaut · 2009 · Cancer Letters
51. p53 and metabolism: from mechanism to therapeutics
    Fernando Moreira Simabuco, Mirian Galliote Morale, Isadora Carolina Betim Pavan, Ana Paula Morelli, Fernando Riback Silva, Rodrigo Esaki Tamura · 2018 · Oncotarget
52. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase
    Harikrishna Nakshatri, Susan E. Rice, Poornima Bhat‐Nakshatri · 2004 · Oncogene
53. Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence
    Lars‐Gunnar Larsson · 2011 · Seminars in Cancer Biology
54. Hypoxia-Inducible Factor 1α Determines Gastric Cancer Chemosensitivity via Modulation of p53 and NF-κB
    Nadine Rohwer, Christof Dame, Anja Haugstetter, Bertram Wiedenmann, Katharina M Detjen, Clemens A. Schmitt, Thorsten Cramer · 2010 · PLoS ONE
55. Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53
    Vikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M., Sabapathy, K. · 2007 · Nucleic Acids Research
56. Update on the Management of Inflammatory Breast Cancer
    Massimo Cristofanilli, Aman U. Buzdar, Gabriel N. Hortobágyi · 2003 · The Oncologist
57. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide
    Natalia Issaeva, Assaf Friedler, Przemyslaw M. Bozko, Klas G. Wiman, Alan Roy Fersht, Galina Selivanova · 2003 · Proceedings of the National Academy of Sciences
58. Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding
    Wenge Wang, Rishu Takimoto, Farzan Rastinejad, Wafik S. El‐Deiry · 2003 · Molecular and Cellular Biology
59. Synergistic effects of PRIMA-1^Met (APR-246) and 5-azacitidine in <i>TP53</i>-mutated myelodysplastic syndromes and acute myeloid leukemia
    Maslah, Nabih, Salomao, Norman, Drevon, Louis, Verger, Emmanuelle, Partouche, Nicolas, Ly, Pierre, Aubin, Philippe, Naoui, Nadia, Schlageter, Marie-Helene, Bally, Cecile et al. · 2020 · Haematologica
60. Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine
    Claudia Fiorini, Marco Cordani, Chiara Padroni, Giovanni Blandino, Silvia Di Agostino, Massimo Donadelli · 2014 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
61. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient
    Klas G. Wiman · 2010 · Oncogene
62. Rescue of mutant p53 transcription function by ellipticine
    Yanhua Peng, Changgong Li, Lihong Chen, Saı̈d M. Sebti, Jiandong Chen · 2003 · Oncogene
63. Kinetic Instability of p53 Core Domain Mutants
    Assaf Friedler, Dmitry B. Veprintsev, Lars O. Hansson, Alan Roy Fersht · 2003 · Journal of Biological Chemistry
64. One, two, three—p53, p63, p73 and chemosensitivity
    M MULLER, Elisa Schulze Schleithoff, Wolfgang Stremmel, Gerry Melino, Peter H. Krammer, Tobias Schilling · 2006 · Drug Resistance Updates
65. p73 in Cancer
    Alessandro Rufini, Massimiliano Agostini, Francesca Grespi, Richard Tomasini, Berna S. Sayan, Maria Victoria Niklison-Chirou, Franco Conforti, Tania Velletri, Antonio Mastino, Tak W. Mak et al. · 2011 · Genes & Cancer
66. Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
    Bykov, Vladimir J. N., Zhang, Qiang, Zhang, Meiqiongzi, Ceder, Sophia, Abrahmsen, Lars, Wiman, Klas G. · 2016 · Frontiers in Oncology
67. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance
    Thorsten Stiewe, Tali E. Haran · 2018 · Drug Resistance Updates
68. Inhibition of p53 inhibitors: progress, challenges and perspectives
    Gema Sanz, Madhurendra Singh, Sylvain Peuget, Galina Selivanova · 2019 · Journal of Molecular Cell Biology
69. PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53
    Roza Zandi, Galina Selivanova, Camilla Laulund Christensen, Thomas Alexander Gerds, Berthe M. Willumsen, Hans Skovgaard Poulsen · 2011 · Clinical Cancer Research
70. Reactivation of p53: from peptides to small molecules
    Christopher John Brown, Chit Fang Cheok, Chandra Shekhar Verma, David Philip Lane · 2010 · Trends in Pharmacological Sciences
71. Targeting p53 for enhanced radio- and chemo-sensitivity
    Chao Lü, Wafik S. El‐Deiry · 2009 · APOPTOSIS
72. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment
    Yan Ru Cui, Gang Guo · 2016 · International Journal of Molecular Sciences
73. CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice
    Xiuwei Tang, Yucui Zhu, Lydia Han, Arianna L. Kim, Levy Kopelovich, David R. Bickers, Mohammad Athar · 2007 · Journal of Clinical Investigation
74. Phase-to-Phase With Nucleoli – Stress Responses, Protein Aggregation and Novel Roles of RNA
    Leena Latonen · 2019 · Frontiers in Cellular Neuroscience
75. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy
    Yao Liu, Xiaohui Wang, Guan Wang, Yu‐Shang Yang, Yong Yuan, Liang Ouyang · 2019 · European Journal of Medicinal Chemistry
76. Erratum: APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
    Xiaoxiao Peng, Meiqiongzi Zhang, Francesca Conserva, Gihan Hosny, Galina Selivanova, Vladimir J.N. Bykov, Elias S.J. Arnér, Klas G. Wiman · 2017 · Cell Death and Disease
77. Small-Molecule Structure Correctors Target Abnormal Protein Structure and Function: Structure Corrector Rescue of Apolipoprotein E4–Associated Neuropathology: Miniperspective
    Mahley, Robert W., Huang, Yadong · 2012 · Journal of Medicinal Chemistry
78. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation
    Yongxing Wang, Young‐Ah Suh, Maren Y. Fuller, James G. Jackson, Shunbin Xiong, Tamara Terzian, Alfonso Quintás‐Cardama, James A. Bankson, Adel K. El‐Naggar, Guillermina Lozano · 2011 · Journal of Clinical Investigation
79. The MYC Oncogene as a Cancer Drug Target
    Heiko Hermeking · 2003 · Current Cancer Drug Targets
80. p53 as a hub in cellular redox regulation and therapeutic target in cancer
    Eriksson, Sofi E, Ceder, Sophia, Bykov, Vladimir J N, Wiman, Klas G · 2019 · Journal of Molecular Cell Biology
81. Tumor suppressor p53 and its gain-of-function mutants in cancer
    Juan Liu, Cen Zhang, Zhaohui Feng · 2013 · Acta Biochimica et Biophysica Sinica
82. Genetic landscape of hepatitis B virus–associated diffuse large B-cell lymphoma
    Weicheng Ren, Xiaofei Ye, Hong Lin Su, Wei Li, Dongbing Liu, Mohammad Pirmoradian, Xianhuo Wang, Bo Zhang, Qiang Zhang, Longyun Chen et al. · 2018 · Blood
83. Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications
    Francesco Perri, Roberto Pacelli, Giuseppina Della Vittoria Scarpati, Laura Cella, Mario Giuliano, Francesco Caponigro, Stefano Pepe · 2014 · Head & Neck
84. Classic and novel roles of p53: prospects for anticancer therapy
    José J. Fuster, Silvia Maria Sanz-Gonzalez, Ute Martha Moll, Vicente Andrés · 2007 · Trends in Molecular Medicine
85. PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
    Perdrix, Anne, Najem, Ahmad, Saussez, Sven, Awada, Ahmad, Journe, Fabrice, Ghanem, Ghanem, Krayem, Mohammad · 2017 · Cancers
86. The cytoplasmic side of p53's oncosuppressive activities
    Anna Comel, Giovanni Sorrentino, Valeria Capaci, Giannino Del Sal · 2014 · FEBS Letters
87. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms
    Antje Lindemann, Ameeta A. Patel, Natalie Lea Silver, Lin Tang, Zhiyi Liu, Li Wang, Noriaki Tanaka, Xiayu Rao, Hideaki Takahashi, Nakachi K. Maduka et al. · 2019 · Clinical Cancer Research
88. p53 tetramerization: at the center of the dominant-negative effect of mutant p53
    Jovanka Gencel‐Augusto, Guillermina Lozano · 2020 · Genes & Development
89. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts
    Wenge Wang, Seok-Hyun Kim, Wafik S. El‐Deiry · 2006 · Proceedings of the National Academy of Sciences
90. Small molecules that reactivate mutant p53
    Vladimir J.N. Bykov, Galina Selivanova, Klas G. Wiman · 2003 · European Journal of Cancer
91. Targeted induction of apoptosis for cancer therapy: current progress and prospects
    Edwin Bremer, Go van Dam, Bart Jan Kroesen, Lou de Leij, Wijnand Helfrich · 2006 · Trends in Molecular Medicine
92. Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising
    Christian Jekimovs, Emma Bolderson, Amila Suraweera, Mark N. Adams, Kenneth John O'Byrne, Derek J. Richard · 2014 · Frontiers in Oncology
93. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer
    Jerson Lima Silva, Elio A. Cino, Iaci N. Soares, Vı́tor F. Ferreira, Guilherme A. P. de Oliveira · 2017 · Accounts of Chemical Research
94. 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells
    Matthias R. Bauer, Andreas C. Joerger, Alan Roy Fersht · 2016 · Proceedings of the National Academy of Sciences
95. The Function of the Mutant p53-R175H in Cancer
    Yen-Ting Chiang, Yi‐Chung Chien, Yuheng Lin, Hui-Hsuan Wu, Dung‐Fang Lee, Yung‐Luen Yu · 2021 · Cancers
96. Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis
    Vera V. Grinkevich, Fedor Nikulenkov, Yao Shi, Martin Enge, Wenjie Bao, Alena Malyukova, Angela Gluch, Alexander E Kel, Olle Sangfelt, Galina Selivanova · 2009 · Cancer Cell
97. Toward the Rational Design of p53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant
    Nicolas Basse, Joel L. Kaar, Giovanni Settanni, Andreas C. Joerger, Trevor J. Rutherford, Alan Roy Fersht · 2010 · Chemistry & Biology
98. Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism
    Srabani Pal, Ashish Bhattacharjee, Asif Ali, Narayan Chandra Mandal, Subhash Chandra Mandal, Mahadeb Pal · 2014 · Journal of Inflammation
99. Mutant p53 targeting by the low molecular weight compound STIMA‐1
    Nicole Zache, Jeremy M.R. Lambert, Nina Rökaeus, Jinfeng Shen, Pierre L. Hainaut, Jan Bergman, Klas G. Wiman, Vladimir J.N. Bykov · 2008 · Molecular Oncology
100. Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
     Nishikawa, Shigeto, Iwakuma, Tomoo · 2023 · Cancers